ETFs Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:35:06 10/02/2026 am IST			5-day change	1st Jan Change
1.395 ^USD	+4.89%		-2.45%	+3.33%

06:14pm	Ocugen Names Rita Johnson-Greene as CFO	MT
05:49pm	Ocugen appoints Rita Johnson-Greene to chief financial officer	RE

ETFs positioned on Ocugen, Inc.

Name	Varia. Jan 1.	Weight	AuM
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	+4.78%	0%	7 M€
VANGUARD US TOTAL MARKET SHARES INDEX ETF	-3.61%	0%	293,477 M€
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	+2.91%	0%	35 M€

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

27/03 - Q4 2025 Earnings Release (Projected)

More about the company